INFLUENZA PATHOGENESIS AND IMMUNOLOGY RESEARCH CENTER:T CELL RESPONSES

这个子项目是许多利用资源的研究子项目之一 由NIH/NCRR资助的中心拨款提供。子项目的主要支持 而子项目的主要调查员可能是由其他来源提供的， 包括其它NIH来源。 列出的子项目总成本可能 代表子项目使用的中心基础设施的估计数量， 而不是由NCRR赠款提供给子项目或子项目工作人员的直接资金。 为了评估人T细胞对甲型和B型流感病毒的应答，我们构建了一个复制限制性重组水疱性口炎病毒的大样本组，每个病毒表达来自各种流感病毒株的单一蛋白。完整的样本组涵盖了2000-2011年使用的流感疫苗株的HA和NA蛋白，以及最近大流行的A/加州/04/09毒株、用于生产常规疫苗的PR 8毒株和用于生产减毒活流感喷雾疫苗的A/安阿伯/06/60毒株的内部组分。我们正在使用这些来测量2010-2011赛季期间接种疫苗的60名供体的T细胞反应。一般而言，CD 8 T细胞对疫苗接种的应答低至不可检测，这一结果并不意外，特别是对于常规灭活疫苗。相比之下，CD 4 T细胞反应更频繁，反应范围为每百万CD 4细胞0-631。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. For assessment of human T cell responses to influenza A and B viruses, we have constructed a large panel of replication-restricted, recombinant vesicular stomatitis viruses, each expressing a single protein from a variety of influenza strains. The complete panel covers the HA and NA proteins from influenza vaccine strains used from 2000-2011, as well as the internal components of the A/California/04/09 strain from the recent pandemic, the PR8 strain that is used for production of the conventional vaccine, and the A/Ann Arbor/06/60 strain that is used for the production of the live-attenuated FluMist vaccine. We are using these to measure T cell responses in 60 donors who were vaccinated during the 2010-2011 season. In general, CD8 T cell responses to vaccination have been low-to-undetectable, a result that was not unexpected, especially for the conventional inactivated vaccine. In contrast, CD4 T cell responses are more frequent, with a response range of 0-631 per million CD4 cells.